Preservation of Urinary Podocyte Markers in Diabetic Kidney Disease by Sodium-Glucose Cotransporter 2 Inhibitor Therapy
Kidney Diseases · 15.03.2025 · 11 (1) · 218-225
DOI: 10.1159/000545225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney Diseases, online erschienen am 15.03.2025. Verfasst von Chuanlei Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong SAR. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) is a standard treatment for kidney and cardiovascular protection in diabetic kidney disease (DKD). We investigated the effect of SGLT2i on the urinary podocyte-associated molecule levels in DKD.
Methods
We studied 24 DKD patients who were started on SGLT2i treatment and 25 patients who were not treated (control group). Urinary levels of podocyte-associated molecules, their corresponding mRNA levels in urinary sediment, estimated glomerular filtration rate (eGFR), and urine albumin-creatinine ratio (UACR) were measured at baseline and 3 months later.
Results
Urinary levels of podocin, podocalyxin, and synaptopodin increased significantly over 3 months in the control group, while the levels remained static in the treatment group. After 3 months of treatment, urinary podocin (2.95 [0.92–5.45] vs. 9.15 [1.88–24.80] ng/μmol-Cr, p < 0.01), podocalyxin (367.3 [299.5–768.6] vs. 920.6 [369.3–2,060.4] ng/μmol-Cr, p < 0.01), and synaptopodin levels (13.17 [9.86–47.02] vs. 35.56 [17.59–134.08] ng/μmol-Cr, p < 0.05) were significantly lower in the treatment than the control group. Urinary sediment mRNA levels of podocin, podocalyxin, synaptopodin, and nephrin did not change in both groups. However, there was no significant correlation between urinary podocyte-associated marker levels and eGFR or UACR at baseline or after treatment.
Conclusion
SGLT2i prevents the progressive increase in the urinary excretion of podocyte-specific molecules in DKD patients, suggesting that SGLT2 inhibitors have a protective effect on the podocytes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Carol and Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine and Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong SAR.
- Li Ka Shing Institute of Health Sciences (LiHS), Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR.
Zitieren
APA
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K. M., & Szeto, C. C. (2025). Preservation of Urinary Podocyte Markers in Diabetic Kidney Disease by Sodium-Glucose Cotransporter 2 Inhibitor Therapy. Kidney Diseases, 11(1), 218-225. https://doi.org/10.1159/000545225
Vancouver
Li C, Ng JK, Chan GC, Fung WW, Chow KM, Szeto CC. Preservation of Urinary Podocyte Markers in Diabetic Kidney Disease by Sodium-Glucose Cotransporter 2 Inhibitor Therapy. Kidney Diseases. 2025;11(1):218-225. doi:10.1159/000545225
BibTeX
@article{Li2025,
author = {Li, Chuanlei and Ng, Jack Kit-Chung and Chan, Gordon Chun-Kau and Fung, Winston Wing-Shing and Chow, Kai-Ming and Szeto, Cheuk-Chun},
title = {Preservation of Urinary Podocyte Markers in Diabetic Kidney Disease by Sodium-Glucose Cotransporter 2 Inhibitor Therapy},
journal = {Kidney Diseases},
year = {2025},
volume = {11},
number = {1},
pages = {218--225},
doi = {10.1159/000545225}
}
EUVIMED